bladder cancer	is a	malignant neoplasm
bladder cancer	is a	type of urinary tract cancer
hematuria	presents with	bladder cancer
painless hematuria	presents with	bladder cancer
smoking	is risk factor for	bladder cancer
aromatic amines	are risk factors for	bladder cancer
aniline dyes	are risk factors for	bladder cancer
schistosomiasis	is risk factor for	bladder cancer
schistosoma haematobium	is risk factor for	squamous cell bladder cancer
urothelial carcinoma	is histology of	bladder cancer
transitional cell carcinoma	is histology of	bladder cancer
non-muscle invasive bladder cancer	is stage	bladder cancer
muscle-invasive bladder cancer	is stage	bladder cancer
hematuria	is symptom of	bladder cancer
urinalysis	detects	hematuria
urine cytology	is test for	bladder cancer
cystoscopy	is diagnostic procedure for	bladder cancer
CT urography	is imaging modality for	bladder cancer
MRI	is imaging modality for	bladder cancer
PET-CT	is imaging modality for	bladder cancer
NMP22	is biomarker for	bladder cancer
FGFR3 mutation	is molecular alteration in	bladder cancer
TP53 mutation	is molecular alteration in	bladder cancer
ERBB2 amplification	is molecular alteration in	bladder cancer
cisplatin-based chemotherapy	is standard regimen for	bladder cancer
carboplatin-based chemotherapy	is alternative regimen for	bladder cancer
neoadjuvant chemotherapy	is used for	muscle-invasive bladder cancer
radiation therapy	is treatment option for	bladder cancer
cystectomy	is definitive treatment for	bladder cancer
TURBT	is first-line procedure for	non-muscle invasive bladder cancer
intravesical BCG therapy	is standard treatment for	non-muscle invasive bladder cancer
intravesical chemotherapy	is option for	non-muscle invasive bladder cancer
urinary diversion	is procedure after	cystectomy
radical cystectomy	is definitive procedure for	muscle-invasive bladder cancer
partial cystectomy	is uncommon for	bladder cancer
BCG therapy	reduces	non-muscle invasive bladder cancer progression
pembrolizumab	is used for	advanced bladder cancer
atezolizumab	is used for	advanced bladder cancer
nivolumab	is used for	advanced bladder cancer
erdafitinib	is used for	bladder cancer with FGFR3 mutation
immunotherapy	is option for	bladder cancer
nephrotoxicity	is adverse effect of	cisplatin-based chemotherapy
renal impairment	limits	cisplatin therapy in bladder cancer
bladder cancer recurrence	occurs after	TURBT
bladder cancer recurrence	occurs after	cystectomy
tumor grade	predicts	bladder cancer prognosis
tumor stage	predicts	bladder cancer prognosis
lymph node metastasis	predicts	bladder cancer prognosis
distant metastasis	predicts	bladder cancer prognosis
surgical margin	predicts	bladder cancer recurrence
pathologic complete response	predicts	bladder cancer survival
urine cytology	has sensitivity for	high-grade bladder cancer
FGFR3 mutation	correlates with	low-grade bladder cancer
BCG therapy	forecasts	recurrence risk in NMIBC
urine cytology	detects	high-grade bladder cancer
imaging	helps evaluate	tumor extent
ureteral invasion	indicates	advanced bladder cancer
perivesical fat invasion	indicates	advanced bladder cancer
pelvic lymph node metastasis	indicates	advanced bladder cancer
bladder cancer treatment goal	is	cure
performance status	influences	treatment choice in bladder cancer
age	influences	prognosis in bladder cancer
comorbidity index	influences	treatment selection in bladder cancer
neutrophil-to-lymphocyte ratio	predicts	bladder cancer prognosis
platelet count	correlates with	bladder cancer prognosis
neuroendocrine bladder cancer	is rare histology of	bladder cancer
small cell bladder cancer	is histology of	bladder cancer
urinary tract infection	mimics	bladder cancer symptoms
bladder cancer	commonly histology	urothelial carcinoma
urothelial carcinoma	is most common histology in	bladder cancer
schistosoma haematobium	associated with	squamous bladder cancer
smoking	increases risk of	bladder cancer mortality
age	increases risk for	bladder cancer mortality
laparoscopic radical cystectomy	used for	bladder cancer
open radical cystectomy	used for	bladder cancer
nerve-sparing cystectomy	recommended in	bladder cancer
urinary diversion	includes	ileal conduit
ileal conduit	is urinary diversion type after	bladder cancer surgery
neobladder	is urinary diversion type after	bladder cancer surgery
radiation therapy	with surgery	improves bladder cancer outcomes
bladder preservation therapy	is used for	non-muscle invasive bladder cancer
upper tract urothelial carcinoma	shares pathogenesis with	bladder cancer
imaging	assesses	tumor extent
biomarker testing	informs	targeted therapy in bladder cancer
drug resistance	emerges in	bladder cancer chemotherapy
recurrence-free survival	is outcome measure in	bladder cancer trials
overall survival	is outcome measure in	bladder cancer trials
